Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.
Also called NCT02072330
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 353 participants
- Sponsor
- Registry
-
NCT02072330
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02072330. Randomized; quadruple masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2013-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
- Condition
- Grade I or II Essential Hypertension
- Intervention (Drug)
- TAK-536CCB
- Intervention (Drug)
- TAK-536CCB + Hydrochlorothiazide
- Intervention (Drug)
- Hydrochlorothiazide
- Intervention (Drug)
- Hydrochlorothiazide
- Intervention (Drug)
- TAK-536CCB + Hydrochlorothiazide
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct02072330- Content hash
a2fbd9ac381af24c604733baf61d6b11ac7d3fdda8afd563282cb0ceb75a5dd0